磐美迪控股

PanMediso Spotlight｜Over $700 Million! Novartis Expands Investment in Radiopharmaceuticals On November 18, 2024, Ratio Therapeutics signed a global exclusive licensing and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis, to develop next-generation SSTR2-targeted radiopharmaceuticals. Under the terms of the agreement, Ratio will receive up to $745 million in upfront and potential milestone payments, along with tiered royalty rights. This collaboration will focus on advancing preclinical activities to identify SSTR2-targeted drug candidates, while Novartis will oversee the remaining development, manufacturing, and commercialization efforts. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #Ratio #Novartis #SSTR2

PanMediso Spotlight｜Covalent Targeted Radiopharmaceuticals Enhance Radionuclide Therapy Efficacy A 2024 Nature article titled "Covalent Targeted Radioligands Potentiate Radionuclide Therapy" introduced a novel class of covalent targeted radiopharmaceuticals (Covalent Targeted Radioligand, CTR). By leveraging ligand-directed bonding reactions and "click chemistry," this innovative approach achieves covalent binding between radioligands and tumor targets, addressing the long-standing challenge of balancing rapid blood clearance and prolonged tumor retention in traditional radiopharmaceuticals. Focusing on fibroblast activation protein (FAP) as a target, the CTR drugs demonstrated enhanced tumor uptake, extended tumor retention, and improved therapeutic efficacy in both mouse models and cancer patients. This groundbreaking technology holds significant clinical potential and is adaptable to the development of other radiopharmaceuticals targeting diverse biological markers. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #Nature #CTR #FAP #nuclide

PanMediso Spotlight｜Novartis' New Radioligand Cancer Therapy Drug Submitted for Approval in China! On November 13, 2024, Novartis' radioligand cancer therapy drug, Lutetium [177Lu] Trastuzumab Injection (Pluvicto), was accepted by China’s National Medical Products Administration (CDE) for review. This PSMA-targeted radioligand therapy was FDA-approved in March 2022 for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This submission indicates that Pluvicto could soon be available in China, offering a new, precision treatment option for prostate cancer patients. Additionally, Novartis’ other radiopharmaceutical, the 68Ga-Gozetotide injection kit, was also accepted, intended for PET scans to identify PSMA-positive prostate cancer lesions. Radiopharmaceuticals' unique "theranostic" capability combines precise tumor targeting with effective cancer cell eradication, showcasing significant therapeutic advantages. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #Novartis #177Lu #Pluvicto #CDE #68Ga #PSMA

PanMediso Spotlight｜Theranostics（IF=12.4）：Alpha-Nuclide Radiation-Driven Bystander Effect | Professor Fei Yu's Team Recently, Professor Fei Yu's team published China's first preclinical study on alpha-nuclides 212Pb/212Bi, titled “Role of Damaged Mitochondrial Transfer in Alpha-Particle Generator 212Pb Radiation-Induced Bystander Effect” in Theranostics (IF=12.4). This study explores how radiation-induced damaged mitochondria act as signaling mediators, facilitating the bystander effect in cancer treatment. The research indicates that molecules in the ICCM may influence the fate of bystander cells, suggesting that indirect tumor cell damage can achieve a broader therapeutic impact. This effect enhances the efficacy of alpha-nuclide therapy in targeting tumor cells beyond the irradiated area, offering a promising approach for cancer treatment. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Nuclide #Theranostics #212Pb #212Bi #ICCM

PanMediso Spotlight｜First Human Study of the GPC3-Targeting Peptide Radiopharmaceutical 68Ga-RAYZ-8009 This study introduces the first human application of the GPC3-targeting radiopharmaceutical 68Ga-RAYZ-8009, focusing on evaluating its potential for diagnosing hepatocellular carcinoma (HCC). By combining with PET/CT, 68Ga-RAYZ-8009 effectively visualizes HCC lesions and provides supplementary information to the existing CT and MRI LI-RADS systems. The study's results indicate that the drug has no significant side effects and can clearly display the hypervascularity of liver tumors in a short time through dynamic scanning, while presenting a good distribution in static images. Preliminary clinical data suggest that 68Ga-RAYZ-8009 not only aids in the early diagnosis of HCC but also has potential as a therapeutic radiopharmaceutical. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #GPC3 #radiopharmaceutical #68Ga #PET 

PanMediso Spotlight｜Novartis Nuclear Medicine Revenue Exceeds $1 Billion in the First Three Quarters Novartis' third-quarter report reveals that global sales of the radioligand therapy Pluvicto reached $386 million, a 50% year-over-year increase, with year-to-date sales surpassing $1.04 billion, up 47%. Pluvicto is a radioligand therapy that combines a small molecule targeting PSMA (prostate-specific membrane antigen) with the radioactive isotope 177Lu. According to Novartis' financial report, the company has submitted a filing for Pluvicto's use in second-line treatment of PSMA-positive mCRPC. Once approved, this indication is expected to drive Pluvicto's sales to new heights for the year. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Nucleardrugs #Novartis #Pluvicto #177Lu #PSMA

PanMediso Spotlight｜Potential Applications of Supramolecular Chemistry in Cancer Diagnostics and Radiopharmaceuticals Supramolecular chemistry shows great potential in cancer treatment and diagnosis, with its material systems capable of rapid generation through self-assembly, flexible chemical synthesis, and reversible non-covalent interactions. On October 28, 2024, Guillermo Moreno-Alcántar, Angela Casini, and others from the Technical University of Munich (Technische Universität München) published a review in Nature Reviews Chemistry. This review focuses on the application advancements of self-assembled complexes and mechanically interlocked molecules, such as metal-organic cages and rotaxanes, as well as in situ-formed supramolecular aggregates in radiopharmaceuticals, emphasizing their potential as the next generation of radiopharmaceutical agents. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #NatureReviewsChemistry  #Radiopharmaceuticals #CancerTreatment #Diagnosis

PanMediso Spotlight｜China Issues "Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026) " As per the Plan, by 2026, the annual direct economic output of the nuclear technology application industry will be to 400 billion RMB, with key technological breakthroughs to be achieved in fields such as medicine, agriculture, and security, and strengthen innovation capabilities and industry standards. https://lnkd.in/gHCxnR8N The Plan outlines seven primary tasks: · Key Technology Advancement: Strengthen foundational research, develop new drugs, radiotherapy technologies, and high-end equipment, and explore the potential applications of nuclear technology in emerging industries like quantum computing, energy storage, and brain-computer interfaces. · Isotope Supply : Accelerate the large-scale production of medical isotopes like Molybdenum-99 and Iodine-125, advance industrial isotope research for isotopes such as Scandium-47 and Iridium-192, and ensure an independent supply of critical isotope products. · Industrial Cluster Development: Foster collaboration along the industry chain, support the growth of industrial clusters and leading enterprises. The Plan outlines various supportive measures to boost industry growth: · Financial and Tax Support: Provide support to nuclear technology application enterprises through national guiding funds and innovative financial instruments. · Industry Regulation Optimization: Streamline approval processes for radioactive drugs and nuclear medical equipment, and strengthen radiation safety and environmental protection regulations. · Basic Services and Talent Development: Promote the construction of public service platforms for testing, inspection, and validation, and support collaborative talent cultivation between universities and enterprises. · Industry Promotion: Enhance public science education and international promotion to aid the global expansion of China's nuclear technology application industry. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #NuclearTechnology #Isotopes #RadioactiveDrugs

PanMediso Spotlight｜China Issues "Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026) " As per the Plan, by 2026, the annual direct economic output of the nuclear technology application industry will be to 400 billion RMB, with key technological breakthroughs to be achieved in fields such as medicine, agriculture, and security, and strengthen innovation capabilities and industry standards. https://lnkd.in/gHCxnR8N The Plan outlines seven primary tasks: · Infrastructure Upgrades: Promote the construction of medical isotope production reactors and optimize existing facilities to fulfill both research and production functions. · Key Technology Advancement: Strengthen foundational research, develop new drugs, radiotherapy technologies, and high-end equipment, and explore the potential applications of nuclear technology in emerging industries like quantum computing, energy storage, and brain-computer interfaces. · Isotope Supply : Accelerate the large-scale production of medical isotopes like Molybdenum-99 and Iodine-125, advance industrial isotope research for isotopes such as Scandium-47 and Iridium-192, and ensure an independent supply of critical isotope products. · Industry Application Promotion: Expand nuclear technology applications in industries such as manufacturing, agriculture, medicine, environmental protection, and public safety to support industrial transformation and upgrading. · New Application Scenarios: Drive the integration of nuclear technology with biotechnology, new materials, and advanced manufacturing, and develop a cross-disciplinary "Nuclear Technology +" platform. · Industrial Cluster Development: Foster collaboration along the industry chain, support the growth of industrial clusters and leading enterprises. · Standards System Establishment: Establish and improve the standard system for nuclear technology applications, promoting mutual recognition of standards domestically and internationally. The Plan outlines various supportive measures to boost industry growth: · Financial and Tax Support: Provide support to nuclear technology application enterprises through national guiding funds and innovative financial instruments. · Industry Regulation Optimization: Streamline approval processes for radioactive drugs and nuclear medical equipment, and strengthen radiation safety and environmental protection regulations. · Basic Services and Talent Development: Promote the construction of public service platforms for testing, inspection, and validation, and support collaborative talent cultivation between universities and enterprises. · Industry Promotion: Enhance public science education and international promotion to aid the global expansion of China's nuclear technology application industry. #NuclearTechnology #Isotopes #RadioactiveDrugs

PanMediso Spotlight｜Application of Nanomedicine Drug Delivery Systems (DDS) Nanovectors have become an essential tool in Targeted Alpha Therapy (TAT) due to their ability to efficiently deliver α-particles directly to tumor cells while precisely releasing radioactive particles. Nanotechnology provides a solid scientific foundation for the clinical translation of TAT, particularly in cases requiring higher doses of radioactivity. Nanocarriers are considered one of the most promising solutions to reduce toxic side effects in such clinical settings. Common nanocarriers for α-radioisotope drugs fall into three categories: lipid-based nanoparticles (NPs), polymer nanoparticles, and inorganic nanoparticles. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #DDS #TAT #NPs #radiopharmaceuticals